Kuros Biosciences AG (USD) Kuros Biosciences AG, a biopharmaceutical firm headquartered in Schlieren, Switzerland, specializes in both bringing to market and advancing therapeutic solutions for tissue repair and bone regeneration. Its global reach extends across the United States, the European Union, and other international markets, with operations strategically divided into Medical Devices, Pharmaceuticals, and a Legacy Portfolio. The company's innovative product lineup includes several key orthobiologics. Their MagnetOs Granules and MagnetOs Putty are already available in the EU and US, serving applications in orthopedics, spinal procedures, and dentistry. Additionally, their fibrin/PTH orthobiologics portfolio features KUR-111, which has successfully concluded Phase 2b clinical trials for treating tibial plateau fractures, and KUR-113, which completed Phase 2b trials for tibial shaft fractures and is currently in Phase II development for spinal interbody fusion. Beyond bone healing, Kuros Biosciences provides advanced sealant solutions, such as Neuroseal, a synthetic tissue sealant approved in the EU and US for preventing cerebrospinal fluid leakage after cranial or spinal surgeries. The company also fosters external partnerships, notably collaborating with Checkmate Pharmaceuticals LLC on the development of CYT003, an oncology treatment.

Kuros Biosciences AG (USD) Active

Wagistrasse 25, Schlieren, CH, 8952

Stock Price USD

Price Change

Last Dividend USD

CSBTF's stock peer is ASCLF (Ascletis Pharma Inc.)

CSBTF's stock peer is CHIZF (China Traditional Chinese Medicine Holdings Co. Limited)

CSBTF's stock peer is CSPHF (CStone Pharmaceuticals)

CSBTF's stock peer is MEOBF (Mesoblast Limited)

CSBTF's stock peer is NPPNY (Nippon Shinyaku Co., Ltd.)

CSBTF's stock peer is NURPF (Neuren Pharmaceuticals Limited)

CSBTF's stock peer is PHGUF (Pharming Group N.V.)

CSBTF's stock peer is PHMMF (Pharma Mar, S.A.)

CSBTF's stock peer is PPTDF (PeptiDream Inc.)

CSBTF's stock peer is SNBIF (SanBio Company Limited)

Healthcare Biotechnology

Kuros Biosciences AG, a biopharmaceutical firm headquartered in Schlieren, Switzerland, specializes in both bringing to market and advancing therapeutic solutions for tissue repair and bone regeneration. Its global reach extends across the United States, the European Union, and other international markets, with operations strategically divided into Medical Devices, Pharmaceuticals, and a Legacy Portfolio. The company's innovative product lineup includes several key orthobiologics. Their MagnetOs Granules and MagnetOs Putty are already available in the EU and US, serving applications in orthopedics, spinal procedures, and dentistry. Additionally, their fibrin/PTH orthobiologics portfolio features KUR-111, which has successfully concluded Phase 2b clinical trials for treating tibial plateau fractures, and KUR-113, which completed Phase 2b trials for tibial shaft fractures and is currently in Phase II development for spinal interbody fusion. Beyond bone healing, Kuros Biosciences provides advanced sealant solutions, such as Neuroseal, a synthetic tissue sealant approved in the EU and US for preventing cerebrospinal fluid leakage after cranial or spinal surgeries. The company also fosters external partnerships, notably collaborating with Checkmate Pharmaceuticals LLC on the development of CYT003, an oncology treatment.

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Recent News

Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich

2026-06-17 01:00:00

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth

2026-05-07 01:00:00

Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026

Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 Financial Highlights Total product sales rose by 51% to USD 43.4 million (Q1 2025: USD 28.8 million) Direct MagnetOs™ product sales increased by 51% to USD 42.9 million (Q1 2025: USD 28.4 million) Group EBITDA reached USD 2.9 million (Q1 2025: EBITDA of USD 2.0 million) Group adjusted EBITDA* amounted to USD 5.7 million, equaling a margin of 13.1% (Q1 2025: USD 3.3 million at 11.6%) Cash and cash equivalents totaled USD 15.7 million, compared to USD 19.8 million as of December 31, 2025, reflecting investments in the diversification and optimization of production capacity to support long-term growth Clinical & Operational Highlights Kuros continued to achieve significant progress in its extremities segment along with strong adoption of MagnetOs MIS in minimally invasive surgeries, reflecting broader adoption across various specialties in multiple care settings A retrospective study led by Dr. Mark Eskander was published in Spine Open and reported an overall fusion rate of 87% for MagnetOs Easypack Putty in a high-risk patient population assessing 70 posterior lumbar fusion patients, with an 84.2% fusion rate in patients assessed at

2026-04-14 01:00:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions